EUVIMEDEUVIMED entdecken
Open Access

Long-term Outcomes and Mixed Response in Nivolumab Therapy for Head and Neck Cancer

Yoh-Ichiro Iwasa, Ryosuke Kitoh, Yoh Yokota, Kentaro Hori, Mariko Kasuga, Shintaro Yamazaki, Yutaka Takumi

In Vivo · 2025

DOI: 10.21873/invivo.14076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2025. Verfasst von Yoh-Ichiro Iwasa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan iwasa@shinshu-u.ac.jp. Hauptthemen laut MEDLINE: Nivolumab, Head and Neck Neoplasms, Antineoplastic Agents, Immunological. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: This study aimed to explore the long-term outcomes of patients with recurrent/metastatic head and neck cancer (RM-HNC) treated with nivolumab in a real-world setting. PATIENTS AND METHODS: We retrospectively analyzed 53 patients with R/M-HNC treated with nivolumab between 2017 and 2024 at the Shinshu University Hospital. Clinical data included response rates, overall survival (OS), progression-free survival 1 (PFS1) 1, PFS2, and immune-related adverse events (irAEs). RESULTS: The median OS was 18.1 months, with 1-year, 2-year, and 4-year survival rates of 57.7%, 37.9%, and 23.3%, respectively. Mixed response (MR) was observed in 17% of patients, and these patients showed significantly better OS than those with progressive disease (p=0.007). Notably, nivolumab was effective in patients not included in the CheckMate 141 criteria, especially in those with nasopharyngeal carcinoma (NPC) showing a favorable prognosis (median OS: 44.0 months). Overall, 13 patients experienced irAEs (24.5%), although this did not significantly affect OS (p=0.170). Long-term survival was observed in 13 patients, with 69.2% of them achieving either complete response or partial response. CONCLUSION: This study provides new insights into the long-term efficacy of nivolumab in R/M-HNC, highlighting the favorable prognosis in NPC and in patients outside the CheckMate 141 criteria. Importantly, this study is the first to report the frequency of MR in HNC, with MR being associated with a significantly better prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabHead and Neck NeoplasmsAntineoplastic Agents, ImmunologicalHumansMaleFemaleMiddle AgedAgedAdultTreatment OutcomeRetrospective StudiesPrognosisImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Nivolumabhead and neck cancerimmune checkpoint Inhibitorprogrammed cell death-1 (PD-1)

Substanzen

NivolumabAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan iwasa@shinshu-u.ac.jp.
  • Department of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine, Matsumoto, Japan.

Zitieren

APA

Iwasa, Y. I., Kitoh, R., Yokota, Y., Hori, K., Kasuga, M., Yamazaki, S., & Takumi, Y. (2025). Long-term Outcomes and Mixed Response in Nivolumab Therapy for Head and Neck Cancer. In Vivo. https://doi.org/10.21873/invivo.14076

Vancouver

Iwasa YI, Kitoh R, Yokota Y, Hori K, Kasuga M, Yamazaki S, et al. Long-term Outcomes and Mixed Response in Nivolumab Therapy for Head and Neck Cancer. In Vivo. 2025. doi:10.21873/invivo.14076

BibTeX
@article{Iwasa2025,
  author = {Iwasa, Yoh-Ichiro and Kitoh, Ryosuke and Yokota, Yoh and Hori, Kentaro and Kasuga, Mariko and Yamazaki, Shintaro and Takumi, Yutaka},
  title = {Long-term Outcomes and Mixed Response in Nivolumab Therapy for Head and Neck Cancer},
  journal = {In Vivo},
  year = {2025},
  doi = {10.21873/invivo.14076}
}
Kostenlos starten →